



Innovative Medicines Initiative

Colm Carroll
27.11.2014 - London

IMI – Europe's partnership for health



> €5 bn




€2.5 bn

Partnership
2008 - 2024




€2.5 bn

An international, cross-sector community



Over 7 000 researchers
59 public-private consortia

Typical IMI 2 project life cycle



IMI2 Call 2: Ebola+ programme

Topics

- Topic 1: Vaccine development Phase I, II, and III
- Topic 2: Manufacturing capability
- Topic 3: Stability of vaccines during transport and storage
- Topic 4: Deployment and compliance of vaccination regimens
- Topic 5: Rapid diagnostic tests

Budget

- Indicative IMI financial contribution: **up to €140 million**
- Indicative contribution by EFPIA companies: **approx. €140 million**

Deadline: 1 December

Upcoming Topics – IMI2 Calls 3 & 4


- 3.1 Remote Assessment of Disease and Relapse – CNS
 - 3.2 Assessing risk and progression of prediabetes and type 2 diabetes to enable disease modification
 - 3.3 Linking clinical neuropsychiatry and quantitative neurobiology
 - 3.4 The consistency approach to quality control in vaccine manufacture
 - 3.5 Pertussis vaccination research
 - 3.6 Knowledge repository to enable patient-focused medicine development
-
- 4.1 Enabling platform on medicines adaptive pathway to patient

Expected Call Launch: 12 December 2014

1. Remote Assessment of Diseases And Relapse (RADAR) Programme

Challenges in Managing Chronic Disease

- Physician visits are **time-limited evaluations** based on **subjective observations** of both the patient and the physician
- **Changes in disease state** for each of these diseases can occur on timescales much **shorter** than the interval between physician visits
- Through technological advances over the last decade it is now possible to **objectively, remotely, and continuously measure** aspects of patient **physiology, behavior and symptoms**



RADAR Topic 1 – CNS

Indicative budget: €11m IMI, €11m Industry contribution

- **Develop and validate the science** of using **biosignatures to characterise disease** and **predict changes** in CNS diseases
- Understand the **regulatory pathways**
- Develop **standards** that enable **seamless integration** of sensor, data capture, data management, & analysis technologies
- Expected **applicant consortium**:
 - **Academic, clinical and disease area experts**
 - **Device and sensor companies**
 - **IT/ analytics expertise**
 - **Regulatory and health-care systems expertise**

Stay in touch

- Visit our website
www.imi.europa.eu
- Sign up to our newsletter
bit.ly/IMInewsletter
- Follow us on Twitter
[@IMI_JU](https://twitter.com/IMI_JU)
- Join our LinkedIn group
bit.ly/LinkedInIMI
- E-mail us
infodesk@imi.europa.eu



The screenshot shows the IMI website homepage. At the top left is the IMI logo and the text 'innovative medicines initiative'. To the right is a banner image of a group of people in a laboratory setting. Below the banner is a navigation menu with links: Home, About IMI, Ongoing projects, Calls for proposals, News, Events & Media, and Reference documents. A central section titled 'THE INNOVATIVE MEDICINES INITIATIVE' provides a brief overview of the organization's mission and its partnership with the European Union and the pharmaceutical industry association EFPIA. To the right, there is a 'IMI NEWSFLASH' section with three entries, each featuring a date and a link to a specific topic or webinar. Below the newsflash is a 'NEWSLETTER' section with a 'Read & subscribe' button and a 'more' link. At the bottom right, there is an 'AGENDA' section listing upcoming events, including the 2nd Annual Meet, a Spring health-related Bk, and a Financial Management Workshop.



The screenshot shows the IMI Twitter profile. At the top left is the IMI logo and the text 'innovative medicines initiative'. To the right is a banner image of a person in a laboratory setting. Below the banner are statistics: 1,285 tweets, 838 following, 2,159 followers, 2 favorites, and 2 lists. The profile bio states: 'The Innovative Medicines Initiative (IMI) is a public-private partnership aiming to speed up the development of better and safer medicines for patients.' The location is listed as Brussels, the website as imi.europa.eu, and the account was joined in June 2010. There are 57 photos and videos. The main content area shows three tweets from IMI (@IMI_JU). The first tweet is from 19h and says: 'Got questions about IMI's #Ebola programme? Check the FAQs and sign up to our webinars on 12/11 and 17/11 bit.ly/IMI2Call2'. The second tweet is from 6h and says: 'IMI #Ebola Topic 5: rapid #diagnostic tests that work in the real world bit.ly/IMI2Call2'. The third tweet is from 6h and says: 'IMI #Ebola Topic 4: using technology to promote #vaccine compliance bit.ly/IMI2Call2'. The fourth tweet is from 6h and says: 'IMI #Ebola Topic 3: tools and technologies for distributing #vaccines that need to be kept very, very cold bit.ly/IMI2Call2'.



Thank you

www.imi.europa.eu

 @IMI_JU